Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Strata Critical Medical, Inc.NASDAQ: SRTA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $5.48M (cash outflow) rose 73.9% year over year, ahead of the -62.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 196.6% from the prior quarter. Over 3 fiscal years it compounded at +147.1% a year.
Context
- Capital expenditures amounted to 5.6% of revenue in FY2025, down 7.7 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +73.9% holds above the trailing-twelve-month pace of -62.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (11.01M) USD
- Year-over-year change
- +66.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.01M) | +66.6% |
| FY2024 | 2024-12-31 | (32.99M) | -1464.4% |
| FY2023 | 2023-12-31 | (2.11M) | -188.9% |
| FY2022 | 2022-12-31 | (730K) | +8.9% |
| FY2021 | 2021-09-30 | (801K) | — |
Capital Expenditures vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -62.4% is the 8th highest of 9, against a peer median of +34.8%.
- Capital expenditures amounts to 5.2% of revenue for SRTA, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $181.17M USD | -23.1% | +24.2% | 11.7% | |
| LTM Mar 2026 | $56.89M USD | +29.1% | -40.4% | 14.8% | |
| LTM Mar 2026 | $38.4M USD | +80.5% | +38.6% | 4.4% | |
| LTM Mar 2026 | $23.86M USD | +40.5% | -6.9% | 13.0% | |
| LTM Mar 2026 | $14.04M USD | +42.5% | +22.3% | 1.1% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $13.18M USD | -62.4% | +147.1% | 5.2% |
| LTM Feb 2026 | $11.71M USD | +98.8% | +130.0% | 3.0% | |
| LTM Mar 2026 | $6.36M USD | -5.4% | +32.0% | 0.8% | |
| LTM Mar 2026 | $4.8M USD | — | +239.1% | 5.5% | |
| LTM Mar 2026 | $1.96M USD | -79.3% | -53.2% | 0.4% | |
| LTM Mar 2026 | £555.43K GBP | — | -47.9% | — | |
| Peer median (excluding SRTA) | — | +34.8% | +23.2% | 4.4% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | 41.35M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 8.19M |
| Deferred Income Tax | (3.64M) | (772K) | (1.47M) | (255K) | 432K |
| Stock-Based Compensation | 9.62M | 8.28M | 12.5M | 19.89M | 17.83M |
| Change in Working Capital | (2.2M) | (17K) | (6.74M) | (3.01M) | (9.08M) |
| Accounts Receivables | (414K) | (5.35M) | (10.25M) | (998K) | (12.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 9.9M | 0 | 0 | 0 |
| Other Working Capital | (1.79M) | (4.57M) | 3.52M | (2.01M) | 2.95M |
| Other Non-Cash Items | 20.06M | (23.08M) | 12.32M | 2.2M | (107.63M) |
| Operating Cash Flow | (15.62M) | (37.13M) | (32.35M) | (2.52M) | (48.91M) |
| Capital Expenditures | (801K) | (730K) | (2.11M) | (32.99M) | (11.01M) |
| Acquisitions (Net) | (23.07M) | (48.1M) | (39K) | (2.23M) | (69.35M) |
| Purchases of Investments | (308.77M) | (228.21M) | (265.97M) | (143.26M) | (146.26M) |
| Sales of Investments | 11.3M | 356.38M | 285.07M | 177.45M | 296.36M |
| Other Investing Activities | (504K) | 0 | 138K | (2.11M) | (1.42M) |
| Investing Cash Flow | (321.34M) | 79.34M | 17.09M | (1.02M) | 69.75M |
| Debt Repayment | (1.17M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 119.63M | 87K | 0 | 0 | 193K |
| Common Stock Repurchased | 0 | 0 | 0 | (244K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 213.79M | (1.17M) | (76K) | (5.52M) | (9.11M) |
| Financing Cash Flow | 332.26M | (1.08M) | (76K) | (5.76M) | (8.91M) |
| Effect of Forex Changes | 10.97M | (4.29M) | (66K) | (80K) | (339K) |
| Net Change in Cash | (4.69M) | 36.84M | (15.4M) | (9.37M) | 11.59M |
| Free Cash Flow | (16.42M) | (37.86M) | (34.46M) | (35.51M) | (59.92M) |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.